Pfizer launches first human trial of experimental eczema treatment
NCT ID NCT06564389
First seen Jan 15, 2026 · Last updated Jun 11, 2026 · Updated 28 times
Summary
This early-stage study tests an experimental drug called PF-07832837 in healthy adults and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug might improve eczema symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anaheim Clinical Trials, LLC
RECRUITINGAnaheim, California, 92801, United States
-
Miami Dermatology and Laser Research
NOT_YET_RECRUITINGMiami, Florida, 33133, United States
-
Paddington Testing Company
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19103, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.